Abstract WP348: Soluble C-type Lectin-Like Receptor 2 as a Biomarker in Patients with Acute Ischemic Stroke or TIA: A Multicenter, Prospective Cohort Study

Background: We measured soluble C-type lectin-like receptor 2 (sCLEC-2), which is a new biomarker of platelet activation, to investigate clinical implications in patients with acute ischemic stroke (AIS) and TIA (Trial registration numbers: NCT05579405, UMIN 000048954). Methods: Plasma levels of sCLEC-2 were measured by high-sensitivity chemiluminescent enzyme immunoassay in 377 patients with AIS and 62 patients with TIA. Results: sCLEC-2/D-dimer ratio (mean±SD) at baseline (Day 1) was higher in patients with non-cardioembolic stroke/TIA (n=111, 491.9±433.7) than in those with cardioembolic stroke/TIA (n=52, 220.6±287.9) (t-test, p1) at discharge was more common in patients with increased sCLEC-2 than in those with decreased sCLEC-2 between Day 1 and Day 7 (61.4% vs 39.1%, Fisher’s exact test, p=0.002). Poor outcome at 3 months was more common in patients with high sCLEC-2 levels (156 pg/ml or more) than in those with normal sCLEC-2 levels (